# A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

> **NCT07075484** · PHASE1 · COMPLETED · sponsor: **China Immunotech (Beijing) Biotechnology Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Autoimmune Hemolytic Anemia

## Interventions

- **DRUG:** YTS109 cell

## Key facts

- **NCT ID:** NCT07075484
- **Lead sponsor:** China Immunotech (Beijing) Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-01-15
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-02-27
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07075484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07075484, "A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07075484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*